Complex Regional Pain Syndrome
Conditions
Brief summary
The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS). Study participants will be randomly assigned to receive either LDN or placebo for a period of several weeks. During this period participants will be asked to attend either in-person or virtual study visits and complete questionnaires.
Interventions
DRUGLDN
DRUGPlacebo
Sugar pill
Sponsors
Stanford University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Upper and/or lower extremity CRPS * On stable treatment for 1 month * CRPS for at least 1 year * Meet the Budapest criteria for CRPS at time of the study.
Exclusion criteria
* Any known allergy to naltrexone or naloxone * Use of prescription opioid analgesics or illegal opioid use * Current or planned pregnancy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in pain severity | Approximately 4 weeks after conclusion of treatment. | Daily pain reports on a 0-10 numerical rating scale for pain, where 0=no pain and 10=pain as bad as you can imagine |
Countries
United States
Contacts
Primary ContactBirute Gedrimaite
Outcome results
None listed